Scarica l'app Stockscreener
19.84
0.35%
0.07
Dopo l'orario di chiusura:
19.83
-0.01
-0.05%
Precedente Chiudi:
$19.77
Aprire:
$19.85
Volume 24 ore:
2.79M
Relative Volume:
0.80
Capitalizzazione di mercato:
$4.74B
Reddito:
$426.45M
Utile/perdita netta:
$197.67M
Rapporto P/E:
24.20
EPS:
0.82
Flusso di cassa netto:
$110.10M
1 W Prestazione:
-2.84%
1M Prestazione:
-17.71%
6M Prestazione:
-1.34%
1 anno Prestazione:
+109.28%
Intervallo 1D:
$19.28
$20.09
Intervallo di 1 settimana:
$19.28
$20.53
Portata 52W:
$9.40
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Nome
Adma Biologics Inc
Settore
Industria
Telefono
(201) 478-5552
Indirizzo
C/O ADMA BIOLOGICS, INC., RAMSEY
Confronta ADMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
19.84 | 4.87B | 426.45M | 197.67M | 110.10M | 0.82 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-19 | Ripresa | Raymond James | Strong Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2021-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Iniziato | Jefferies | Buy |
| 2019-04-15 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-07 | Ripresa | H.C. Wainwright | Buy |
| 2017-12-11 | Reiterato | Maxim Group | Buy |
| 2017-11-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2016-08-01 | Downgrade | Maxim Group | Buy → Hold |
| 2016-07-25 | Reiterato | Maxim Group | Buy |
| 2015-05-13 | Reiterato | Maxim Group | Buy |
| 2014-12-08 | Iniziato | Oppenheimer | Outperform |
| 2014-12-01 | Reiterato | Maxim Group | Buy |
Mostra tutto
Adma Biologics Inc Borsa (ADMA) Ultime notizie
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - sharewise
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
Where are the Opportunities in (ADMA) - news.stocktradersdaily.com
Cetera Investment Advisers Decreases Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Adma Biologics director sells $182,635 in common stock - Investing.com Australia
Adma Biologics director sells $182,635 in common stock By Investing.com - Investing.com South Africa
Bank of America Corp DE Has $13.14 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Exploring High Growth Tech Stocks In The US May 2025 - Yahoo
Are Options Traders Betting on a Big Move in ADMA Biologics Stock? - The Globe and Mail
BNP Paribas Financial Markets Sells 674,016 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Ameriprise Financial Inc. Acquires 88,542 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date - The Globe and Mail
(ADMA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
FY2025 EPS Estimates for ADMA Biologics Decreased by Analyst - Defense World
Amid Bumpy Biotech Trade, I'm Eyeing These Two Stocks - TheStreet Pro
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics (NASDAQ:ADMA) Rating Lowered to “Sell” at StockNews.com - Defense World
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - The Globe and Mail
Revenue Gains, Bold Guidance Lift ADMA Shares - FXEmpire
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates - MSN
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Reports Strong Growth and Strategic Advances - TipRanks
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond - GuruFocus
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond James | ADMA Stock News - GuruFocus
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? - Yahoo Finance
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits - MSN
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Adma Biologics price target raised to $32 from $25 at Raymond James - TipRanks
Raymond James Increases Price Target for ADMA Biologics | ADMA Stock News - GuruFocus
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Future Outlook - GuruFocus
Adma Biologics: Q1 Earnings Snapshot - New Haven Register
ADMA Biologics Reports Strong Q1 2025 Financial Growth - TipRanks
ADMA Biologics Inc earnings missed by $0.01, revenue topped estimates - Investing.com Nigeria
ADMA Options Activity Suggests Anticipated Post-Earnings Volatil - GuruFocus
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, R - GuruFocus
ADMA Biologics Q1 Earnings, Revenue Rise; Shares Fall After Hours - marketscreener.com
Earnings call transcript: ADMA Biologics Q1 2025 sees revenue beat, mixed stock reaction - Investing.com
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
ADMA Biologics (ADMA) Misses Revenue Estimates Despite Strong Growth - GuruFocus
ADMA Biologics Announces $500M Share Repurchase Program - TipRanks
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, Revenue of $114.8M Misses Expectations - GuruFocus
Earnings Flash (ADMA) Adma Biologics Posts Q1 Diluted EPS $0.11, vs. FactSet Est of $0.15 - marketscreener.com
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Adma Biologics options imply 10.9% move in share price post-earnings - TipRanks
ADMA Options Activity Suggests Anticipated Post-Earnings Volatility | ADMA Stock News - GuruFocus
3 Mid-Cap Medical Stocks Outperforming the Market - Investing.com
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - Zacks Investment Research
Adma Biologics Inc Azioni (ADMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):